<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6885">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05071612</url>
  </required_header>
  <id_info>
    <org_study_id>MARIPOSA</org_study_id>
    <nct_id>NCT05071612</nct_id>
  </id_info>
  <brief_title>Parallel Arm Trial of AD109 and AD504 In Patients With OSA</brief_title>
  <acronym>MARIPOSA</acronym>
  <official_title>Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Arm Dose Finding Study to Compare Fixed Dose Combinations of AD109 and AD504 to Atomoxetine or Placebo in Obstructive Sleep Apnea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apnimed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apnimed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2 randomized double-blind placebo-controlled parallel-arm dose finding study&#xD;
      to compare fixed dose combinations of AD109 and AD504 to atomoxetine or placebo in&#xD;
      Obstructive Sleep Apnea.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in AHI, combined AD109 dose arms vs. combined placebo arms</measure>
    <time_frame>28 Days</time_frame>
    <description>Change in AHI (AHI, average number of events for every hour of sleep) measured by polysomnography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in AHI, combined AD504 dose arms vs. combined placebo arms</measure>
    <time_frame>28 Days</time_frame>
    <description>Change in AHI (AHI, average number of events for every hour of sleep) measured by polysomnography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AHI, combined atomoxetine dose arms vs. combined placebo arms</measure>
    <time_frame>28 Days</time_frame>
    <description>Change in AHI (AHI, average number of events for every hour of sleep) measured by polysomnography</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>OSA - Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>AD109 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AD109 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AD504 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AD504 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atomoxetine 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Atomoxetine 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD109</intervention_name>
    <description>Oral administration at bedtime</description>
    <arm_group_label>AD109 Dose 1</arm_group_label>
    <arm_group_label>AD109 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD504</intervention_name>
    <description>Oral administration at bedtime</description>
    <arm_group_label>AD504 Dose 1</arm_group_label>
    <arm_group_label>AD504 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atomoxetine Hydrochloride</intervention_name>
    <description>Oral administration at bedtime</description>
    <arm_group_label>Atomoxetine 1</arm_group_label>
    <arm_group_label>Atomoxetine 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration at bedtime</description>
    <arm_group_label>Placebo 1</arm_group_label>
    <arm_group_label>Placebo 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 18 to 65 years of age for men and 18-75 for women, inclusive, at the Screening&#xD;
             Visit.&#xD;
&#xD;
          -  Mean AHI 10 to 45 events/h, inclusive&#xD;
&#xD;
          -  PGI-S: &gt;1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current clinically significant sleep disorder other than OSA&#xD;
&#xD;
          -  Clinically significant craniofacial malformation.&#xD;
&#xD;
          -  Clinically significant cardiac disease (e.g. rhythm disturbances, coronary artery&#xD;
             disease or heart failure or hypertension requiring more than 2 medications for&#xD;
             control).&#xD;
&#xD;
          -  Participants with a history of using devices for OSA treatment, including CPAP, oral&#xD;
             or nasal devices, or positional devices, may enroll as long as the devices have not&#xD;
             been used for at least 2 weeks prior to first PSG and are not used during&#xD;
             participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ron Farkas, MD PhD</last_name>
    <phone>617-500-8880</phone>
    <email>info@apnimed.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Luigi Taranto, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Redwood City</city>
        <state>California</state>
        <zip>94063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>619-294-4302</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SDS Clinical Trials, Inc.</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Tuttle</last_name>
      <phone>714-834-1565</phone>
      <email>charlotte@sdsclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Andrew O Schreiber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delta Waves</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steve Li</last_name>
      <phone>719-262-9283</phone>
      <phone_ext>227</phone_ext>
      <email>research@deltawaves.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teradan Clinical Trials</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Centers of America -- Hollywood</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>May Fernandez</last_name>
      <phone>954-549-3469</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NeuroTrials Research, Inc.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Talia Williams</last_name>
      <phone>404-851-9934</phone>
      <email>twilliams@neurotrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sleep Disorders Centers of the Mid-Atlantic (SDCMA)</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tanya Alexander, CCRC</last_name>
      <phone>410-582-9300</phone>
      <phone_ext>113</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>248-344-6672</phone>
      <email>Cdrake1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Christopher L. Drake, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital Sleep Medicine</name>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inessa Lokshina</last_name>
      <phone>314-205-6011</phone>
      <email>SLHSleepResearch@stlukes-stl.com</email>
    </contact>
    <investigator>
      <last_name>Paula K. Schweitzer, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Health Care, P.A.</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wanda Small, LPN</last_name>
      <phone>252-639-5984</phone>
      <email>wsmall@cchealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTI Clinical Research Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>513-281-3868</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intrepid Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>513-977-8888</phone>
      <email>info@intrepidresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brian Abaluck, LLC</name>
      <address>
        <city>Malvern</city>
        <state>Pennsylvania</state>
        <zip>19355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Quinn, MPH</last_name>
      <phone>484-588-5314</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>September 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2021</study_first_posted>
  <last_update_submitted>December 3, 2021</last_update_submitted>
  <last_update_submitted_qc>December 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atomoxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

